trial

A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia

NCTId NCT01626885
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 42 (actual)
Sponsored by Tanabe Pharma Corporation
Primary completion 2014-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
42 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2012-05
Primary completion
2014-06
Eligibility
ALL · 20 Years · 64 Years

Interventions & indications

Drugs
MP-214

Sponsors

Tanabe Pharma CorporationLead Sponsor

Sites

0 total

Linked catalysts

1
A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophre — primary completion2014-06

Facts & assertions

4 sourced
Enrollment
42
Phase
PHASE2,PHASE3
Primary Completion Date
2014-06
Status
COMPLETED
relationships
The graph out of here
drug
MP-214
drug
lead_sponsor
Tanabe Pharma Corporation
company
indication
Schizophrenia
indication
Schizophrenia
indication
Mental Disorders
indication